EE177 Cost of Adverse Events With the Bruton Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib in the First-Line Treatment of Chronic Lymphocytic Leukemia in Brazil
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.561
https://www.valueinhealthjournal.com/article/S1098-3015(25)03118-3/fulltext
Title :
EE177 Cost of Adverse Events With the Bruton Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib in the First-Line Treatment of Chronic Lymphocytic Leukemia in Brazil
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)03118-3&doi=10.1016/j.jval.2025.09.561
First page :
Section Title :
Open access? :
No
Section Order :
10154